Finanzen von GoodRx Holdings Inc (GDRX)GDRXGoodRx Holdings Inc

Evaluating the bottom line, GoodRx Holdings, Inc. maintains a gross margin of 78.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.21%, while the net margin is 4.26%. These profitability ratios, combined with a Return on Equity (ROE) of 2.52%, provide a clear picture of how effectively GDRX converts its operational activities into shareholder value.

In the context of the broader market, GDRX competes directly with industry leaders such as OPK and LMRI. With a market capitalization of $1.18B, it holds a significant position in the sector. When comparing efficiency, GDRX's gross margin of 78.41% stands against OPK's 37.32% and LMRI's 10.90%. Such benchmarking helps identify whether GoodRx Holdings, Inc. is trading at a premium or discount relative to its financial performance.

GoodRx's revenue for Q2 2026 was $200.41 million, slightly down from $203.07 million in Q2 2025, indicating a slight decline in growth. The gross margin is currently at 78.41%, which is healthy, but the net income has shown volatility, dropping significantly in recent quarters.